Low-dose version of Prempro approved

Share this article:
The FDA approved a low-dose version of Wyeth Pharmaceuticals' hormone replacement therapy Prempro (conjugated estrogens and medroxyprogesterone). The low-dose Prempro has 28 percent less estrogen and 40 percent less progestin than full-dose Prempro, Wyeth reported. It contains 0.45 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone. This version is indicated for use in the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats. It is also approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, such as vaginal dryness. Wyeth said data supporting the efficacy and tolerability of low-dose Prempro is based on the Women's HOPE study, which included 2,805 postmenopausal women.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.